Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies.
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2017
At a glance
- Drugs Milatuzumab (Primary)
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 18 Nov 2010 Results will presented at the 52nd ASH Annual Meeting, according to an Immunomedics media release.
- 24 Jun 2009 Planned end date changed from Dec 2008 to Jun 2010 as reported by ClinicalTrials.gov.
- 17 Aug 2007 New trial record.